Canccord Genuity Morning Coffee on Johnson & Johnson (JNJ); Good for the Bones, ja!
Tweet Send to a FriendGet Alerts JNJ Hot Sheet
Price: $86.36 --0%
Rating Summary:
8 Buy, 9 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Rating Summary:
8 Buy, 9 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Trade JNJ Now!
Canccord Genuity Morning Coffee on Johnson & Johnson (NYSE: JNJ); Good for the bones, ja!
Johnson & Johnson expects to complete its $19.7-billion purchase of Swiss medical device maker Synthes today and says the deal will slightly boost company profit this year, rather than being a moderate drag on earnings as previously expected. Synthes makes a wide variety of medical devices, from metal disks that fit into spinal cords to plates used to fuse broken bones together. For J&J, the orthopaedic market has been called an important growth driver and Synthes already does a substantial business in key emerging markets like Russia, China and India. To receive approval from both U.S. and European regulators, J&J agreed to divest its DePuy Orthopaedics subsidiary to Biomet. The company said that the largest in the company’s history and will give it a line of profitable tools and materials used in trauma surgery and should boost 2012 earnings by $0.03-0.05 a share. Industry analysts, on average, had expected J&J's full-year earnings to rise about 2% this year to $5.12 per share. The company expects the acquisition to boost 2013 earnings, excluding special items, by $0.10-0.15 cents per share."
To see more ratings on JNJ, Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Johnson & Johnson expects to complete its $19.7-billion purchase of Swiss medical device maker Synthes today and says the deal will slightly boost company profit this year, rather than being a moderate drag on earnings as previously expected. Synthes makes a wide variety of medical devices, from metal disks that fit into spinal cords to plates used to fuse broken bones together. For J&J, the orthopaedic market has been called an important growth driver and Synthes already does a substantial business in key emerging markets like Russia, China and India. To receive approval from both U.S. and European regulators, J&J agreed to divest its DePuy Orthopaedics subsidiary to Biomet. The company said that the largest in the company’s history and will give it a line of profitable tools and materials used in trauma surgery and should boost 2012 earnings by $0.03-0.05 a share. Industry analysts, on average, had expected J&J's full-year earnings to rise about 2% this year to $5.12 per share. The company expects the acquisition to boost 2013 earnings, excluding special items, by $0.10-0.15 cents per share."
To see more ratings on JNJ, Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Johnson & Johnson (JNJ) Acquires Privatly-Held Aragon Pharmaceuticals for $650M, Plus Contingencies
- Madison Square Garden (MSG) is a Stock to Own on Sport Team Value and Hidden Value of The Garden - Needham & Company
- Lazard Raises PT on Chicago Bridge & Iron (CBI) to $75
Create E-mail Alert Related Categories
Analyst Comments, Mergers and AcquisitionsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
